For research use only. Not for therapeutic Use.
(E/Z)-BCI（Cat No.:I017619）is a dual inhibitor of DUSP6 (dual-specificity phosphatase 6) and DUSP1, which are negative regulators of the MAPK/ERK signaling pathway. By inhibiting these phosphatases, (E/Z)-BCI enhances ERK activity, leading to prolonged MAPK signaling. This compound is widely used in research to study cell differentiation, proliferation, and survival, particularly in developmental biology and cancer. (E/Z)-BCI has shown potential in modulating cellular responses to growth factors and has been explored for its role in therapeutic strategies aimed at promoting regeneration or targeting diseases driven by aberrant ERK signaling.
| Catalog Number | I017619 |
| CAS Number | 15982-84-0 |
| Molecular Formula | C₂₂H₂₃NO |
| Purity | ≥95% |
| Target | Apoptosis |
| IUPAC Name | (2Z)-2-benzylidene-3-(cyclohexylamino)-3H-inden-1-one |
| InChI | InChI=1S/C22H23NO/c24-22-19-14-8-7-13-18(19)21(23-17-11-5-2-6-12-17)20(22)15-16-9-3-1-4-10-16/h1,3-4,7-10,13-15,17,21,23H,2,5-6,11-12H2/b20-15- |
| InChIKey | XJDKPLZUXCIMIS-HKWRFOASSA-N |
| SMILES | C1CCC(CC1)NC\2C3=CC=CC=C3C(=O)/C2=C\C4=CC=CC=C4 |
| Reference | [1]. Zhang F, et al. DUSP6 Inhibitor (E/Z)-BCI Hydrochloride Attenuates Lipopolysaccharide-Induced Inflammatory Responses in Murine Macrophage Cells via Activating the Nrf2 Signaling Axis and Inhibiting the NF-κB Pathway. Inflammation. 2019 Apr;42(2):672-681.<br>[2]. Wu QN,et al. Pharmacological inhibition of DUSP6 suppresses gastric cancer growth and metastasis and overcomes cisplatin resistance. Cancer Lett. 2018 Jan 1;412:243-255. |
